Citation: | ZHANG Xiao-hong, HUANG Zhi-miao, ZHU Ying, . Effect and mechanism of miR-135b on apoptosis of HCT116 colon cancer cells[J]. Chinese Journal of Public Health, 2022, 38(6): 783-786. doi: 10.11847/zgggws1134110 |
[1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2018, 68(6): 394 – 424. doi: 10.3322/caac.21492
|
[2] |
Thanikachalam K, Khan G. Colorectal cancer and nutrition[J]. Nutrients, 2019, 11(1): 164. doi: 10.3390/nu11010164
|
[3] |
Ng C, Li HJ, Wu WKK, et al. Genomics and metagenomics of colorectal cancer[J]. Journal of Gastrointestinal Oncology, 2019, 10(6): 1164 – 1170. doi: 10.21037/jgo.2019.06.04
|
[4] |
Dawson H, Kirsch R, Messenger D, et al. A review of current challenges in colorectal cancer reporting[J]. Archives of Pathology and Laboratory Medicine, 2019, 143(7): 869 – 882. doi: 10.5858/arpa.2017-0475-RA
|
[5] |
Saberinia A, Alinezhad A, Jafari F, et al. Oncogenic miRNAs and target therapies in colorectal cancer[J]. Clinica Chimica Acta, 2020, 508: 77 – 91. doi: 10.1016/j.cca.2020.05.012
|
[6] |
Liu GK, Li BQ. Role of miRNA in transformation from normal tissue to colorectal adenoma and cancer[J]. Journal of Cancer Research and Therapeutics, 2019, 15(2): 278 – 285.
|
[7] |
Li L, Wang AL, Cai M, et al. Identification of stool miR-135b-5p as a non-invasive diaognostic biomarker in later tumor stage of colorectal cancer[J]. Life Sciences, 2020, 260: 118417. doi: 10.1016/j.lfs.2020.118417
|
[8] |
Wu CW, Ng SC, Dong YJ, et al. Identification of microRNA-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma[J]. Clinical Cancer Research, 2014, 20(11): 2994 – 3002. doi: 10.1158/1078-0432.CCR-13-1750
|
[9] |
袁平, 张小鸿, 王家兴, 等. 血清miR-135b在结直肠癌中的表达及临床意义[J]. 慢性病学杂志, 2019, 20(8): 1121 – 1124.
|
[10] |
陈明倩, 马莉, 滕银成. miR-135b在肿瘤发生发展中的研究进展[J]. 医学综述, 2018, 24(24): 4836 – 4841. doi: 10.3969/j.issn.1006-2084.2018.24.010
|
[11] |
Chen Z, Gao YJ, Gao SH, et al. MiR-135b-5p promotes viability, proliferation, migration and invasion of gastric cancer cells by targeting Kruppel-like factor 4 (KLF4)[J]. Archives of Medical Science, 2020, 16(1): 167 – 176. doi: 10.5114/aoms.2019.87761
|
[12] |
Gao JS, Zhang L, Liu ZA, et al. Effect of miR-135b inhibitor on biological characteristics of osteosarcoma cells through up-regulating PPM1A[J]. International Journal of Clinical and Experimental Pathology, 2019, 12(3): 689 – 699.
|
[13] |
Hu ML, Zhu SX, Xiong SW, et al. MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer (Review)[J]. Oncology Reports, 2019, 41(3): 1439 – 1454.
|
[14] |
Frankson R, Yu ZH, Bai YP, et al. Therapeutic targeting of oncogenic tyrosine phosphatases[J]. Cancer Research, 2017, 77(21): 5701 – 5705. doi: 10.1158/0008-5472.CAN-17-1510
|
[15] |
Chen CY, Chen JY, He LN, et al. PTEN: Tumor suppressor and metabolic regulator[J]. Frontiers in Endocrinology (Lausanne), 2018, 9: 338. doi: 10.3389/fendo.2018.00338
|
[16] |
Álvarez-Garcia V, Tawil Y, Wise HM, et al. Mechanisms of PTEN loss in cancer: It's all about diversity[J]. Seminars in Cancer Biology, 2019, 59: 66 – 79. doi: 10.1016/j.semcancer.2019.02.001
|
[17] |
Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review[J]. Breast Cancer Research and Treatment, 2018, 169(3): 397 – 406. doi: 10.1007/s10549-018-4697-y
|
[18] |
Marquard FE, Jucker M. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer[J]. Biochemical Pharmacology, 2020, 172: 113729. doi: 10.1016/j.bcp.2019.113729
|
[19] |
Wu YY, Hu G, Wu RL, et al. High expression of miR-135b predicts malignant transformation and poor prognosis of gastric cancer[J]. Life Sciences, 2020, 257: 118133. doi: 10.1016/j.lfs.2020.118133
|